1. Home
  2. STG vs IMUX Comparison

STG vs IMUX Comparison

Compare STG & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sunlands Technology Group

STG

Sunlands Technology Group

N/A

Current Price

$5.64

Market Cap

112.4M

Sector

Real Estate

ML Signal

N/A

Logo Immunic Inc.

IMUX

Immunic Inc.

HOLD

Current Price

$0.68

Market Cap

85.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
STG
IMUX
Founded
2003
2016
Country
China
United States
Employees
N/A
N/A
Industry
Other Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
112.4M
85.8M
IPO Year
2018
N/A

Fundamental Metrics

Financial Performance
Metric
STG
IMUX
Price
$5.64
$0.68
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$6.00
AVG Volume (30 Days)
7.7K
1.2M
Earning Date
11-20-2025
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
4.01
N/A
Revenue
$285,589,112.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$1.45
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.28
$0.56
52 Week High
$15.00
$1.42

Technical Indicators

Market Signals
Indicator
STG
IMUX
Relative Strength Index (RSI) 44.53 40.71
Support Level $4.84 $0.67
Resistance Level $5.99 $0.73
Average True Range (ATR) 0.41 0.05
MACD 0.07 -0.00
Stochastic Oscillator 44.91 13.66

Price Performance

Historical Comparison
STG
IMUX

About STG Sunlands Technology Group

Sunlands Technology Group is a provider of online post-secondary and professional education services in China. The company offers various degree- and diploma-oriented post-secondary courses through its online platforms. In addition, it provides online professional courses and educational content to help students prepare for professional certification exams and attain professional skills. The Group has one operating segment, which is the provision of online education services.

About IMUX Immunic Inc.

Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.

Share on Social Networks: